Pharmacological methods of expressing paternal UBE3A, while successful at initiating protein expression, have not been characterized to ameliorate Angelman syndrome phenotypes in vivo (Huang et al., 2012; King et al., 2013; Powell et al., 2013). Here, UBE3A is linked to Angelman syndrome.